DBV Technologies | DBVT - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amarin USD 624.36M 21.4M 2026-06
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
DBV Technologies USD 223.2M 43.2M 2026-06
Galectin Therapeutics USD 27.65M 1.76M 2024-06
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Incyte USD 7.87B 533.53M 2026-06
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03